Saturday 17 October 2026
Export JAGX’s income statement to Excel — free account
Jaguar Animal Health, Inc.
JAGX Healthcare Biotechnology
Jaguar Animal Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.5 million, down 1.52% from fiscal 2024. In the quarter to June 2026, revenue fell 58.9%, EPS grew 95.6%, free cash flow grew 13.8% and total debt fell 83.9%, each against the same quarter a year earlier.
3.53
1.06
−23.09%
Follow JAGX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.02 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.09 | 0.23 | 0.19 | 0.30 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(0.46) | 0.76 | (0.39) | (0.76) | |
P/B ratio |
0.49 | 0.00 | 0.00 | 1.89 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
(0.03) | 0.32 | 0.96 | 0.79 | |
EV/EBITDA |
0.04 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
0.12 | (1.24) | (0.46) | (0.36) | |
EV/FCF |
0.11 | (1.13) | (0.45) | (0.35) | |
Quick Ratio |
0.27 | 0.25 | 0.23 | 0.14 | |
Current Ratio |
0.69 | 0.50 | 0.50 | 0.81 | |
Net Debt/EBITDA |
0.73 | 0.09 | (0.35) | (0.62) | |
Debt/Assets |
5.05% | 29.59% | 39.36% | 15.46% | |
Debt/Equity |
0.35 | (0.70) | (0.81) | 1.75 | |
Asset Turnover |
0.67 | 0.67 | 0.25 | 0.22 | |
Operating CF/Net income |
0.42 | (1.26) | 0.24 | 0.49 | |
Capex/Depreciation |
0.00 | 0.00 | (0.06) | (0.10) | |
Interest Coverage |
(47.19) | 14.57 | (160.92) | (1,206.33) | |
Research and Development Expense of Revenue |
272.33% | 19.38% | 442.44% | 118.65% | |
Selling, General and Administrative Expense of Revenue |
363.67% | 24.68% | 221.45% | 198.86% | |
Intangible Assets out of Total Assets |
0.44 | 0.42 | 0.42 | 0.35 | |
Share Based Compensation of Revenue |
13.96% | 0.76% | 3.59% | 4.38% | |
Graham Net Nets |
(4.83) | (4.92) | (17.05) | (4.43) | |
Graham Number |
1,925.64 | 5,861.40 | 35,872.10 | 0.00 | |
Earnings Yield |
4,018.78% | (1,711.98%) | (2,431.58%) | (2,083.08%) | |
Free Cash Flow Yield |
(303.37%) | (122.81%) | (1,133.29%) | (751.81%) | |
Revenue per Share |
22.69 | 589.30 | 735.23 | 1,063.10 | |
Operating CF per Share |
(98.85) | 256.69 | (1,247.27) | (1,616.90) | |
Capex per Share |
0.00 | 0.00 | (9.32) | (18.62) | |
Free Cash Flow per Share |
(98.85) | 256.69 | (1,256.59) | (1,635.52) | |
Cash per Share |
122.04 | 292.56 | 1,780.00 | 1,216.21 | |
Shareholders Equity per Share |
91.13 | (457.91) | (4,247.27) | 1,503.10 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
91.13 | (457.91) | (4,247.27) | 1,503.10 | |
Free Cash Flow |
(5.34) | 8.83 | (5.53) | (4.74) | |
Working Capital |
(7.85) | (20.48) | (20.31) | (6.72) | |
Capital Expenditures |
— | — | (0.04) | (0.05) | |
Net Current Asset Value |
(11.74) | (32.98) | (36.67) | (15.71) | |
EV/EBIT |
0.03 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.76 | 0.83 | 1.67 | 1.41 | |
Average Payables |
5.71 | 5.99 | 6.99 | 6.50 | |
Average Inventory |
9.02 | 9.19 | 9.47 | 10.15 | |
Average Assets |
41.23 | 44.45 | 45.87 | 53.97 | |
Average Common Equity |
4.66 | (7.46) | (7.34) | 7.49 |
Columns are period end dates · fundamentals updated 2 Oct 2026